AAIC 2021 | Beyond Aβ and p-Tau: novel biomarkers under investigation for Alzheimer’s disease

Amyloid β (Aβ) and phosphorylated tau (p-tau) are used widely as diagnostic biomarkers for Alzheimer’s disease and new modalities and assessment methods continue to be heavily investigated. Nicholas Ashton, PhD, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, discusses other novel biomarkers that are currently under investigation. Dr Ashton highlights blood-based glial fibrillary acidic protein (GFAP) as a potentially beneficial biomarker in early-stage disease. Inflammation biomarkers detected by imaging or in the cerebral spinal fluid are also an area of interest. This interview took place during the Alzheimer’s Association International Conference (AAIC) 2021.